Skip to content

Artificial intelligence-based ultrasound-assisted diagnosis system for subtype identification of breast tumors

Artificial intelligence-based ultrasound-assisted diagnosis system for subtype identification of breast tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122714
Enrollment
Unknown
Registered
2026-04-16
Start date
2026-05-05
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast neoplasms

Interventions

Gold Standard:Pathological diagnosis
Index test:Deep Learning-Based AI Analysis System for Breast Ultrasound Imaging

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Retrospective Development Stage: 1. Patients with breast tumors who underwent surgical treatment at our hospital (and cooperative centers) from January 1, 2020, to December 31, 2025; 2. Complete archived preoperative breast ultrasound images are available; 3. Clear postoperative pathological diagnosis reports are available. Prospective Validation Stage: 1. Newly diagnosed patients with breast tumors scheduled to undergo surgical treatment at our hospital starting from May 5, 2026; 2. Patients who agree to participate in this study and have signed the informed consent form; 3. Patients who will receive preoperative breast ultrasound examination according to routine clinical practice.

Exclusion criteria

Exclusion criteria: Retrospective Development Stage: 1. Patients who received neoadjuvant therapy (chemotherapy, targeted therapy, etc.) preoperatively, which may significantly alter the ultrasonic characteristics of tumors; 2. Patients with poor ultrasound image quality, missing key sections, or severe artifacts that severely affect image analysis; 3. Patients with unclear pathological diagnosis, incomplete reports, or inability to accurately match with imaging findings. Prospective Validation Stage: 1. Patients scheduled to undergo surgery after neoadjuvant therapy; 2. Patients with other severe diseases who are expected to be unable to complete surgical treatment or follow-up; 3 .Patients unable to cooperate in completing ultrasound examination.

Design outcomes

Primary

MeasureTime frame
Sensitivity;Specificity;AUC;

Countries

China

Contacts

Public ContactShan Dandan

Shanghai Tenth People's Hospital

shandandan2014@163.com+86 21 6630 7539

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026